Year All News202420232022202120202019201820172016 Apr 4 2024 Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights Read More + Apr 4 2024 Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning Read More + Feb 5 2024 Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference Read More +
Apr 4 2024 Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights Read More +
Apr 4 2024 Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning Read More +
Feb 5 2024 Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference Read More +